Centre hospitalier universitaire de Québec - CHUL
Québec, Quebec, G1V 4G2, Canada
NCT Number: NCT01493648
This proposal will explore muscle function (strength and endurance) in men and women suffering from statin-induced muscle symptoms. The mechanisms responsible for these muscle symptoms will be explored. Also, the investigators will assess the potential usefulness of vitamin D supplementation in a randomized control trial.
Looking for future studies?
Notify Me30 year–60 year
All sexes
Interventional
Not applicable
Québec, Quebec, G1V 4G2, Canada
Statins are a class of drugs that are widely prescribed to lower blood cholesterol levels. Although they have few side effects, many patients report muscle pain, cramps, and weakness when using these drugs. We know very little on the real impact of these muscle symptoms on patient quality of life, especially in relation to muscle strength and endurance.
Patients under statin therapy will stop medication for 2 months. Results from blood sample, muscle function and muscle biopsy (in some participants) will be compared with baseline. Participants will then take vitamin D supplementation or placebo for one month. Thereafter, statin will be reintroduced for two months while continuing vitamin D or placebo supplementation. At the end of that time, measures from blood sample, muscle function and muscle biopsy will be compared with other visits.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants will receive weekly doses of 30,000 IU of vitamin D for 3 months.
Other names: Cholecalciferol, D-tabs
Participants will receive placebo (lactose 100 mg) for 3 months.
Time frame: Change from baseline at 2 months
Time frame: Change from baseline at 2 months
Strenght and endurance evaluation
Time frame: Change from baseline at 2 months
Histological, ultrastructural and metabolic assessment of muscle biopsy.
Time frame: Change from baseline at 5 months
Time frame: Change from baseline at 5 months
Time frame: Change from baseline at 5 months
CHU de Quebec-Universite Laval
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05625945
Cardiovascular Diseases, HMG COA Reductase Inhibitor Adverse Reaction
Nijmegen, Netherlands
View Trial DetailsNCT05011643
Cardiovascular Diseases, HMG COA Reductase Inhibitor Adverse Reaction
Nijmegen, Netherlands
View Trial DetailsNCT01702987
Dyslipidemias, HMG COA Reductase Inhibitor Adverse Reaction
Boston, Massachusetts, United States
View Trial DetailsNCT01032993
Asthenia, Cramps
Boston, Massachusetts, United States
View Trial Details